$SLNO

Soleno Therapeutics faces securities lawsuit alleging undisclosed safety risks in its sole commercial product DCCR. Investors have until May 5, 2026 to seek lead plaintiff status.

Law firm Bernstein Liebhard files securities fraud class action against $SLNO, citing alleged misrepresentations regarding Phase 3 DCCR clinical trial program.

Class action lawsuit filed against $SLNO alleging failure to disclose safety concerns about DCCR drug candidate, including fluid retention issues in clinical trials.

$SLNO investors urged to join class action over undisclosed DCCR safety concerns; May 5, 2026 deadline.

Soleno Therapeutics faces class action lawsuit over alleged failure to disclose safety issues with drug DCCR, following 12-27% stock declines from August-September 2025 revelations.

Law firm investigates securities fraud claims against ASP Isotopes, Integer Holdings, Molina Healthcare, and Soleno Therapeutics for alleged misstatements regarding technology, competitive position, medical costs, and drug safety.

Soleno Therapeutics faces securities lawsuit after hyperphagia drug VYKAT XR launch falters amid safety concerns, driving shares down 40% since August short seller report.

Soleno Therapeutics ($SLNO) faces class action lawsuit alleging executives failed to disclose material safety concerns with its lead drug DCCR, with lead plaintiff deadline set for May 5, 2026.

Soleno Therapeutics faces securities fraud lawsuit over alleged safety misstatements in DCCR clinical trial. Stock fell 26% following August short-seller report.

Soleno Therapeutics faces securities fraud lawsuit alleging failure to disclose safety concerns about DCCR drug candidate between March 2025 and November 2026.

Soleno Therapeutics faces class action lawsuit over DCCR safety concealment claims, with investors suffering significant losses following critical short-seller report and patient death disclosure.

Four public companies face securities fraud investigations alleging misrepresentation of core operations, product safety, and regulatory compliance.

Law firm Kahn Swick & Foti alleges Soleno Therapeutics failed to disclose material safety concerns with its flagship DCCR product, with lead plaintiff applications due May 5, 2026.

Rosen Law Firm files securities class action against REGENXBIO for alleged false statements on product safety and efficacy, with April 14, 2026 lead plaintiff deadline.

Class action lawsuit filed against $SLNO over alleged securities fraud tied to DCCR safety concerns, patient death, and disappointing Q3 results that triggered sharp stock declines.

Rosen Law Firm files class action against Soleno Therapeutics for allegedly concealing fluid retention safety concerns in DCCR clinical trials, affecting drug viability.

Class action lawsuit filed against $SLNO over alleged securities fraud tied to DCCR drug safety concerns, patient death, and disappointing Q3 results.

Soleno Therapeutics faces class action lawsuit for allegedly concealing drug safety risks including fluid retention and diabetes complications. Affected shareholders can claim losses through May 2026.

Grabar Law Office investigates securities fraud claims against $ASPI, $CWH, $EOSE, and $SLNO for alleged disclosure failures. Long-term shareholders may seek compensation and reforms at no cost.

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.